Positive data for PTC124, one of the first potential therapies to address the basic defect in CF were published today in The Lancet. The Phase 2 data show that treatment with PTC124 improves the function of the faulty
|
1 min read
Share this article
Topics
About the CF Foundation
|
CFTR Modulators
|
Genetic Therapies
CF Foundation Reflects on Progress Toward Equity, Racial Justice, Diversity, and Inclusion
News |
4 min read
CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method
News |
2 min read
CF Foundation Urges Vertex Pharmaceuticals to Reverse Consequential Decision on Copay Assistance
News |
3 min read
Stay up to date with The Foundation
Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.